Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1115 (LINC01115) is a human long non-coding RNA classified as a lincRNA, meaning its transcript does not overlap protein-coding genes and does not code for protein itself[1][3][4]. LINC01115 is typically over 200 nucleotides in length. Like other lincRNAs, LINC01115 regulates gene expression, often by modulating the activity of microRNAs, RNA-binding proteins, or chromatin structure[4][5]. Aberrant expression of LINC01115 has been associated with several cancers, including retinoblastoma and others, where it may promote tumor cell proliferation and migration by acting as a molecular sponge for specific microRNAs[2]. However, it is not specifically classified as a therapeutic receptor, enzyme, channel, transporter, or traditional drug target, and there are no known direct pharmacological agents that interact with LINC01115 currently in clinical use[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1115 (LINC01115).